Conventional magnetic resonance imaging (MRI) at 1.5 Tesla (T) is limited by modest spatial resolution and signal-to-noise ratio (SNR), impeding the identification and classification of inflammatory central nervous system changes in current clinical practice. Gaining from enhanced susceptibility effects and improved SNR, ultrahigh field MRI at 7 T depicts inflammatory brain lesions in great detail. This review summarises recent reports on 7 T MRI in neuroinflammatory diseases and addresses the question as to whether ultrahigh field MRI may eventually improve clinical decision-making and personalised disease management.

Berlin Ultrahigh Field Facility Max Delbrueck Center for Molecular Medicine Robert Roessle Strasse 10 13125 Berlin Germany

Clinical and Experimental Multiple Sclerosis Research Center Department of Neurology Charité Universitaetsmedizin Berlin Charitéplatz 1 10117 Berlin Germany

Department of Neurology and Center of Clinical Neuroscience Charles University Prague 1st Faculty of Medicine and General University Hospital Prague Kateřinská 30 128 21 Praha 2 Czech Republic

Department of Neurology Asklepios Fachklinikum Teupitz Buchholzer Str 21 15755 Teupitz Germany

Department of Neurology Charité Universitaetsmedizin Berlin Charitéplatz 1 10117 Berlin Germany

Experimental and Clinical Research Center Charité Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine Robert Roessle Strasse 10 13125 Berlin Germany

Institute of Neuroradiology Universitaetsmedizin Goettingen Robert Koch Straße 40 37075 Goettingen Germany

Medical Image Analysis Center Mittlere Strasse 83 CH 4031 Basel Switzerland

NeuroCure Clinical Research Center Charité Universitaetsmedizin Berlin Charitéplatz 1 10117 Berlin Germany

Zobrazit více v PubMed

Holland GN, Moore WS, Hawkes RC. Nuclear magnetic resonance tomography of the brain. J Comput Assist Tomogr. 1980;4:1–3. doi: 10.1097/00004728-198002000-00001. PubMed DOI

Filippi M, Rocca MA, De Stefano N, Enzinger C, Fisher E, Horsfield MA, et al. Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol. 2011;68:1514–20. doi: 10.1001/archneurol.2011.914. PubMed DOI

Kuchling J, Sinnecker T, Bozin I, Dörr J, Madai VI, Sobesky J, et al. Ultrahigh field MRI in context of neurological diseases. Nervenarzt. 2014;85(4):445–58. doi: 10.1007/s00115-013-3967-5. PubMed DOI

Golubnitschaja O, Costigliola V. EPMA. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012;3:1–53. doi: 10.1007/s13167-011-0137-3. PubMed DOI PMC

Haacke E, Brown R, Thompson M, Venkatesan R. Magnetic resonance imaging: physical principles and sequence design. John Wiley & Sons (USA). 1999. p. 378.

Moser E, Stahlberg F, Ladd ME, Trattnig S. 7-T MR—from research to clinical applications? NMR Biomed. 2012;25:695–716. doi: 10.1002/nbm.1794. PubMed DOI

Gizewski ER, Maderwald S, Linn J, Dassinger B, Bochmann K, Forsting M, et al. High-resolution anatomy of the human brain stem using 7-T MRI: improved detection of inner structures and nerves? Neuroradiology. 2014;56:177–86. doi: 10.1007/s00234-013-1312-0. PubMed DOI

Strotmann B, Heidemann RM, Anwander A, Weiss M, Trampel R, Villringer A, et al. High-resolution MRI and diffusion-weighted imaging of the human habenula at 7 tesla. J Magn Reson Imaging. 2014;39:1018–26. doi: 10.1002/jmri.24252. PubMed DOI

Graessl A, Renz W, Hezel F, Dieringer MA, Winter L, Oezerdem C, et al. Modular 32-channel transceiver coil array for cardiac MRI at 7.0T: modular transceiver coil array for cardiac MRI. Magn Reson Med. 2014;72:276–90. doi: 10.1002/mrm.24903. PubMed DOI

Graessl A, Muhle M, Schwerter M, Rieger J, Oezerdem C, Santoro D, et al. Ophthalmic magnetic resonance imaging at 7 T using a 6-channel transceiver radiofrequency coil array in healthy subjects and patients with intraocular masses. Invest Radiol. 2014;49:260–70. doi: 10.1097/RLI.0000000000000049. PubMed DOI

Thalhammer C, Renz W, Winter L, Hezel F, Rieger J, Pfeiffer H, et al. Two-dimensional sixteen channel transmit/receive coil array for cardiac MRI at 7.0 T: design, evaluation, and application. J Magn Reson Imaging. 2012;36:847–57. doi: 10.1002/jmri.23724. PubMed DOI PMC

Atkinson IC, Renteria L, Burd H, Pliskin NH, Thulborn KR. Safety of human MRI at static fields above the FDA 8 T guideline: sodium imaging at 9.4 T does not affect vital signs or cognitive ability. J Magn Reson Imaging. 2007;26:1222–7. doi: 10.1002/jmri.21150. PubMed DOI

Chakeres DW, Bornstein R, Kangarlu A. Randomized comparison of cognitive function in humans at 0 and 8 Tesla. J Magn Reson Imaging. 2003;18:342–5. doi: 10.1002/jmri.10366. PubMed DOI

Theysohn J. Subjective acceptance of 7T: initial experience in the first 210 subjects. Proc Intl Soc Mag Reson Med. 2008;16:1049.

Möller HE, von Cramon DY. Survey of risks related to static magnetic fields in ultra high field MRI. Rofo – Fortschr Rontg. 2008;180:293–301. doi: 10.1055/s-2008-1027227. PubMed DOI

Fatahi M, Reddig A, Friebe B, Reinhold D, Speck O. Analysis of DNA double-strand breaks in human peripheral blood mononuclear cells after exposure to 7T MRI. ISMRM Toronto, Canada. 2015;2015:0300.

Klix S, Els A, Paul K, Graessl A, Oezerdem C, Weinberger O, et al. On the subjective acceptance during cardiovascular magnetic resonance imaging at 7.0 Tesla. PLOS ONE. 2015;10 doi: 10.1371/journal.pone.0117095. PubMed DOI PMC

Chakeres DW, de Vocht F. Static magnetic field effects on human subjects related to magnetic resonance imaging systems. Prog Biophys Mol Biol. 2005;87:255–65. doi: 10.1016/j.pbiomolbio.2004.08.012. PubMed DOI

Kangarlu A, Robitaille P-ML. Biological effects and health implications in magnetic resonance imaging. Concepts Magn Reson. 2000;12:321–59. doi: 10.1002/1099-0534(2000)12:5<321::AID-CMR4>3.0.CO;2-J. DOI

Lee JW, Kim MS, Kim YJ, Choi YJ, Lee Y, Chung HW. Genotoxic effects of 3 T magnetic resonance imaging in cultured human lymphocytes. Bioelectromagnetics. 2011;32:535–42. doi: 10.1002/bem.20664. PubMed DOI

Knuuti J, Saraste A, Kallio M, Minn H. Is cardiac magnetic resonance imaging causing DNA damage? Eur Heart J. 2013;34:2337–9. doi: 10.1093/eurheartj/eht214. PubMed DOI

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302. doi: 10.1002/ana.22366. PubMed DOI PMC

Doering A, Pfueller CF, Paul F, Dörr J. Exercise in multiple sclerosis—an integral component of disease management. EPMA J. 2012;3:2. doi: 10.1007/s13167-011-0136-4. PubMed DOI PMC

Dörr J, Doering A, Paul F. Can we prevent or treat multiple sclerosis by individualised vitamin D supply. EPMA J. 2013;4:1–12. doi: 10.1186/1878-5085-4-4. PubMed DOI PMC

Urbanek C, Weinges-Evers N, Bellmann-Strobl J, Bock M, Dorr J, Hahn E, et al. Attention Network Test reveals alerting network dysfunction in multiple sclerosis. Mult Scler J. 2010;16:93–9. doi: 10.1177/1352458509350308. PubMed DOI

Weinges-Evers N, Brandt AU, Bock M, Pfueller CF, Dorr J, Bellmann-Strobl J, et al. Correlation of self-assessed fatigue and alertness in multiple sclerosis. Mult Scler J. 2010;16:1134–40. doi: 10.1177/1352458510374202. PubMed DOI

Bellmann-Strobl J, Wuerfel J, Aktas O, Dörr J, Wernecke KD, Zipp F, et al. Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis. Neurology. 2009;73:1624–7. doi: 10.1212/WNL.0b013e3181c1de4f. PubMed DOI

Veauthier C, Paul F. Fatigue in multiple sclerosis: which patient should be referred to a sleep specialist? Mult Scler J. 2012;18:248–9. doi: 10.1177/1352458511411229. PubMed DOI

Finke C, Pech LM, Sömmer C, Schlichting J, Stricker S, Endres M, et al. Dynamics of saccade parameters in multiple sclerosis patients with fatigue. J Neurol. 2012;259:2656–63. doi: 10.1007/s00415-012-6565-8. PubMed DOI

Wieder L, Gäde G, Pech LM, Zimmermann H, Wernecke K-D, Dörr J, et al. Low contrast visual acuity testing is associated with cognitive performance in multiple sclerosis: a cross-sectional pilot study. BMC Neurol. 2013;13:167. doi: 10.1186/1471-2377-13-167. PubMed DOI PMC

Scheel M, Finke C, Oberwahrenbrock T, Freing A, Pech L, Schlichting J, et al. Retinal nerve fibre layer thickness correlates with brain white matter damage in multiple sclerosis: a combined optical coherence tomography and diffusion tensor imaging study. Mult Scler J. 2014;20:190–7. doi: 10.1177/1352458514535128. PubMed DOI

Zimmermann H, Freing A, Kaufhold F, Gaede G, Bohn E, Bock M, et al. Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. Mult Scler J. 2013;19:443–50. doi: 10.1177/1352458512457844. PubMed DOI

Oberwahrenbrock T, Ringelstein M, Jentschke S, Deuschle K, Klumbies K, Bellmann-Strobl J, et al. Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Mult Scler J. 2013;19:1887–95. doi: 10.1177/1352458513489757. PubMed DOI

Bock M, Brandt AU, Kuchenbecker J, Dorr J, Pfueller CF, Weinges-Evers N, et al. Impairment of contrast visual acuity as a functional correlate of retinal nerve fibre layer thinning and total macular volume reduction in multiple sclerosis. Br J Ophthalmol. 2012;96:62–7. doi: 10.1136/bjo.2010.193581. PubMed DOI

Bock M, Brandt AU, Dorr J, Pfueller CF, Ohlraun S, Zipp F, et al. Time domain and spectral domain optical coherence tomography in multiple sclerosis: a comparative cross-sectional study. Mult Scler J. 2010;16:893–6. doi: 10.1177/1352458510365156. PubMed DOI

Brandt AU, Oberwahrenbrock T, Ringelstein M, Young KL, Tiede M, Hartung HP, et al. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain. 2011;134 doi: 10.1093/brain/awr095. PubMed DOI

Simon J. Very early MS—insights from MRI. Mult Scler J. 2012;18:1372–6. doi: 10.1177/1352458512452925. PubMed DOI

Londono AC, Mora CA. Nonconventional MRI biomarkers for in vivo monitoring of pathogenesis in multiple sclerosis. Neurol Neuroimmunol Neuroinflammation. 2014;1 doi: 10.1212/NXI.0000000000000045. PubMed DOI PMC

Ciccarelli O, Barkhof F, Bodini B, De Stefano N, Golay X, Nicolay K, et al. Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. Lancet Neurol. 2014;13:807–22. doi: 10.1016/S1474-4422(14)70101-2. PubMed DOI

Huhn K, Lämmer R, Oberwahrenbrock T, Lämmer A, Waschbisch A, Gosar D, et al. Optical coherence tomography in patients with a history of juvenile multiple sclerosis reveals early retinal damage. Eur J Neurol. 2015;22:86–92. doi: 10.1111/ene.12532. PubMed DOI

Finke C, Schlichting J, Papazoglou S, Scheel M, Freing A, Soemmer C, et al. Altered basal ganglia functional connectivity in multiple sclerosis patients with fatigue. Mult Scler J. 2015;21:925–34. doi: 10.1177/1352458514555784. PubMed DOI

Pfueller CF, Brandt AU, Schubert F, Bock M, Walaszek B, Waiczies H, et al. Metabolic changes in the visual cortex are linked to retinal nerve fiber layer thinning in multiple sclerosis. PLoS ONE. 2011;6 doi: 10.1371/journal.pone.0018019. PubMed DOI PMC

Bellmann-Strobl J, Stiepani H, Wuerfel J, Bohner G, Paul F, Warmuth C, et al. MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study. Eur Radiol. 2009;19:2066–74. doi: 10.1007/s00330-009-1364-z. PubMed DOI

Streitberger K-J, Sack I, Krefting D, Pfüller C, Braun J, Paul F, et al. Brain viscoelasticity alteration in chronic-progressive multiple sclerosis. PLoS ONE. 2012;7 doi: 10.1371/journal.pone.0029888. PubMed DOI PMC

Charil A, Yousry TA, Rovaris M, Barkhof F, De Stefano N, Fazekas F, et al. MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation”. Lancet Neurol. 2006;5:841–52. doi: 10.1016/S1474-4422(06)70572-5. PubMed DOI

Solomon AJ, Klein EP, Bourdette D. “Undiagnosing” multiple sclerosis: the challenge of misdiagnosis in MS. Neurology. 2012;78:1986–91. doi: 10.1212/WNL.0b013e318259e1b2. PubMed DOI PMC

Hohlfeld R. “Gimme five”: future challenges in multiple sclerosis. ECTRIMS Lecture 2009. Mult Scler J. 2010;16:3–14. doi: 10.1177/1352458509357355. PubMed DOI

Dörr J, Bitsch A, Schmailzl KJG, Chan A, Von Ahsen N, Hummel M, et al. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology. 2009;73:991–3. doi: 10.1212/WNL.0b013e3181b878f6. PubMed DOI

Stroet A, Hemmelmann C, Starck M, Zettl U, Dörr J, Paul F, et al. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord. 2012;5:75–9. doi: 10.1177/1756285611433318. PubMed DOI PMC

Dörr J, Paul F. The transition from first-line to second-line therapy in multiple sclerosis. Curr Treat Options Neurol. 2015;17:354. doi: 10.1007/s11940-015-0354-5. PubMed DOI

Borisow N, Doering A, Pfueller CF, Paul F, Dörr J, Hellwig K. Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy. EPMA J. 2012;3:9. doi: 10.1186/1878-5085-3-9. PubMed DOI PMC

Li V, Kane J, Chan HH, Hall AJ, Butzkueven H. Continuing fingolimod after development of macular edema: a case report. Neurol-Neuroimmunol Neuroinflammation. 2014;1 doi: 10.1212/NXI.0000000000000013. PubMed DOI PMC

Clausi V, Giannecchini S, Magnani E, Repice A, Mechi C, Martelli F, et al. Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy. Neurol Neuroimmunol Neuroinflammation. 2015;2:e58––8. doi: 10.1212/NXI.0000000000000058. PubMed DOI PMC

Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler J. 2015 PubMed

Tallantyre EC, Morgan PS, Dixon JE, Al- RA, Brookes MJ, Morris PG, et al. 3 Tesla and 7 Tesla MRI of multiple sclerosis cortical lesions. J Magn Reson Imaging. 2010;32:971–7. doi: 10.1002/jmri.22115. PubMed DOI

Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain J Neurol. 2007;130:1089–104. doi: 10.1093/brain/awm038. PubMed DOI

Schmierer K, Parkes HG, So P-W, An SF, Brandner S, Ordidge RJ, et al. High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis. Brain J Neurol. 2010;133:858–67. doi: 10.1093/brain/awp335. PubMed DOI

Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, Bergmann M, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128:2705–12. doi: 10.1093/brain/awh641. PubMed DOI

Calabrese M, Poretto V, Favaretto A, Alessio S, Bernardi V, Romualdi C, et al. Cortical lesion load associates with progression of disability in multiple sclerosis. Brain J Neurol. 2012;135:2952–61. doi: 10.1093/brain/aws246. PubMed DOI

DeLuca GC, Yates RL, Beale H, Morrow SA. Cognitive impairment in multiple sclerosis: clinical, radiologic and pathologic insights. Brain Pathol Zurich Switz. 2015;25:79–98. doi: 10.1111/bpa.12220. PubMed DOI PMC

Nielsen AS, Kinkel RP, Madigan N, Tinelli E, Benner T, Mainero C. Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS. Neurology. 2013;81:641–9. doi: 10.1212/WNL.0b013e3182a08ce8. PubMed DOI PMC

Geurts JJG, Bö L, Pouwels PJW, Castelijns JA, Polman CH, Barkhof F. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. Am J Neuroradiol. 2005;26:572–7. PubMed PMC

Geurts JJG, Pouwels PJW, Uitdehaag BMJ, Polman CH, Barkhof F, Castelijns JA. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology. 2005;236:254–60. doi: 10.1148/radiol.2361040450. PubMed DOI

Yao B, Hametner S, van Gelderen P, Merkle H, Chen C, Lassmann H, et al. 7 Tesla magnetic resonance imaging to detect cortical pathology in multiple sclerosis. PloS One. 2014;9 doi: 10.1371/journal.pone.0108863. PubMed DOI PMC

Abdel-Fahim R, Mistry N, Mougin O, Blazejewska A, Pitiot A, Retkute R, et al. Improved detection of focal cortical lesions using 7T magnetisation transfer imaging in patients with multiple sclerosis. Mult Scler Relat Disord. 2014;3:258–65. doi: 10.1016/j.msard.2013.10.004. PubMed DOI

Kilsdonk ID, de Graaf WL, Soriano AL, Zwanenburg JJ, Visser F, Kuijer JPA, et al. Multicontrast MR imaging at 7T in multiple sclerosis: highest lesion detection in cortical gray matter with 3D-FLAIR. Am J Neuroradiol. 2013;34:791–6. doi: 10.3174/ajnr.A3289. PubMed DOI PMC

de Graaf WL, Kilsdonk ID, Lopez-Soriano A, Zwanenburg JJM, Visser F, Polman CH, et al. Clinical application of multi-contrast 7-T MR imaging in multiple sclerosis: increased lesion detection compared to 3 T confined to grey matter. Eur Radiol. 2013;23:528–40. doi: 10.1007/s00330-012-2619-7. PubMed DOI

Sinnecker T, Mittelstaedt P, Dörr J, Pfueller CF, Harms L, Niendorf T, et al. Multiple sclerosis lesions and irreversible brain tissue damage: a comparative ultrahigh-field strength magnetic resonance imaging study. Arch Neurol. 2012;69:739–45. doi: 10.1001/archneurol.2011.2450. PubMed DOI

Nielsen AS, Kinkel RP, Tinelli E, Benner T, Cohen-Adad J, Mainero C. Focal cortical lesion detection in multiple sclerosis: 3 Tesla DIR versus 7 Tesla FLASH-T2. J Magn Reson Imaging. 2012;35:537–42. doi: 10.1002/jmri.22847. PubMed DOI PMC

Peterson JW, Bö L, Mörk S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001;50:389–400. doi: 10.1002/ana.1123. PubMed DOI

Kollia K, Maderwald S, Putzki N, Schlamann M, Theysohn JM, Kraff O, et al. First clinical study on ultra-high-field MR imaging in patients with multiple sclerosis: comparison of 1.5T and 7T. Am J Neuroradiol. 2009;30:699–702. doi: 10.3174/ajnr.A1434. PubMed DOI PMC

Mainero C, Benner T, Radding A, van der Kouwe A, Jensen R, Rosen BR, et al. In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Neurology. 2009;73:941–8. doi: 10.1212/WNL.0b013e3181b64bf7. PubMed DOI PMC

Pitt D, Boster A, Pei W, Wohleb E, Jasne A, Zachariah CR, et al. Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging. Arch Neurol. 2010;67:812–8. doi: 10.1001/archneurol.2010.148. PubMed DOI

Metcalf M, Xu D, Okuda DT, Carvajal L, Srinivasan R, Kelley DAC, et al. High-resolution phased-array MRI of the human brain at 7 tesla: initial experience in multiple sclerosis patients. J Neuroimaging. Off J Am Soc Neuroimaging. 2010;20:141–7. doi: 10.1111/j.1552-6569.2008.00338.x. PubMed DOI PMC

Fischer MT, Wimmer I, Höftberger R, Gerlach S, Haider L, Zrzavy T, et al. Disease-specific molecular events in cortical multiple sclerosis lesions. Brain J Neurol. 2013;136:1799–815. doi: 10.1093/brain/awt110. PubMed DOI PMC

Cohen-Adad J, Benner T, Greve D, Kinkel RP, Radding A, Fischl B, et al. In vivo evidence of disseminated subpial T2* signal changes in multiple sclerosis at 7 T: a surface-based analysis. NeuroImage. 2011;57:55–62. doi: 10.1016/j.neuroimage.2011.04.009. PubMed DOI PMC

Harrison DM, Oh J, Roy S, Wood ET, Whetstone A, Seigo MA, et al. Thalamic lesions in multiple sclerosis by 7T MRI: clinical implications and relationship to cortical pathology. Mult Scler J. 2015. doi:10.117/1352458514558134. PubMed PMC

van Walderveen MA, Barkhof F, Hommes OR, Polman CH, Tobi H, Frequin ST, et al. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology. 1995;45:1684–90. doi: 10.1212/WNL.45.9.1684. PubMed DOI

Sailer M, Losseff NA, Wang L, Gawne-Cain ML, Thompson AJ, Miller DH. T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A prospective 18 months follow-up study. Eur J Neurol Off J Eur Fed Neurol Soc. 2001;8:37–42. PubMed

Mistry N, Tallantyre EC, Dixon JE, Galazis N, Jaspan T, Morgan PS, et al. Focal multiple sclerosis lesions abound in “normal appearing white matter”. Mult Scler J. 2011;17:1313–23. doi: 10.1177/1352458511415305. PubMed DOI

Tallantyre EC, Morgan PS, Dixon JE, Al- RA, Brookes MJ, Evangelou N, et al. A comparison of 3T and 7T in the detection of small parenchymal veins within MS lesions. Invest Radiol. 2009;44:491–4. doi: 10.1097/RLI.0b013e3181b4c144. PubMed DOI

Tallantyre EC, Brookes MJ, Dixon JE, Morgan PS, Evangelou N, Morris PG. Demonstrating the perivascular distribution of MS lesions in vivo with 7-Tesla MRI. Neurology. 2008;70:2076–8. doi: 10.1212/01.wnl.0000313377.49555.2e. PubMed DOI

Kuchling J, Ramien C, Bozin I, Dörr J, Harms L, Rosche B, et al. Identical lesion morphology in primary progressive and relapsing-remitting MS—an ultrahigh field MRI study. Mult Scler J. 2014;20:1866–71. doi: 10.1177/1352458514531084. PubMed DOI

Absinta M, Sati P, Gaitán MI, Maggi P, Cortese ICM, Filippi M, et al. Seven-tesla phase imaging of acute multiple sclerosis lesions: a new window into the inflammatory process. Ann Neurol. 2013;74:669–78. doi: 10.1002/ana.23959. PubMed DOI PMC

Bian W, Harter K, Hammond-Rosenbluth KE, Lupo JM, Xu D, Kelley DA, et al. A serial in vivo 7T magnetic resonance phase imaging study of white matter lesions in multiple sclerosis. Mult Scler J. 2013;19:69–75. doi: 10.1177/1352458512447870. PubMed DOI

Radaideh AM A, Wharton SJ, Lim S-Y, Tench CR, Morgan PS, Bowtell RW, et al. Increased iron accumulation occurs in the earliest stages of demyelinating disease: an ultra-high field susceptibility mapping study in Clinically Isolated Syndrome. Mult Scler J. 2013;19:896–903. doi: 10.1177/1352458512465135. PubMed DOI

Hametner S, Wimmer I, Haider L, Pfeifenbring S, Brück W, Lassmann H. Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol. 2013;74:848–61. doi: 10.1002/ana.23974. PubMed DOI PMC

Bagnato F, Hametner S, Yao B, van Gelderen P, Merkle H, Cantor FK, et al. Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. Brain J Neurol. 2011;134:3602–15. doi: 10.1093/brain/awr278. PubMed DOI PMC

Adams CW. Perivascular iron deposition and other vascular damage in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1988;51:260–5. doi: 10.1136/jnnp.51.2.260. PubMed DOI PMC

Bozin I, Ge Y, Kuchling J, Dusek P, Chawla S, Harms L, et al. Magnetic resonance phase alterations in multiple sclerosis patients with short and long disease duration. PLoS One. 2015;10(7):e0128386. PubMed PMC

Connor JR, Menzies SL. Relationship of iron to oligodendrocytes and myelination. Glia. 1996;17:83–93. doi: 10.1002/(SICI)1098-1136(199606)17:2<83::AID-GLIA1>3.0.CO;2-7. PubMed DOI

Sinnecker T, Dörr J, Pfueller CF, Harms L, Ruprecht K, Jarius S, et al. Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology. 2012;79:708–14. doi: 10.1212/WNL.0b013e3182648bc8. PubMed DOI

Kister I, Herbert J, Zhou Y, Ge Y. Ultrahigh-field MR (7 T) imaging of brain lesions in neuromyelitis optica. Mult Scler Int. 2013 PubMed PMC

Tallantyre EC, Dixon JE, Donaldson I, Owens T, Morgan PS, Morris PG, et al. Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions. Neurology. 2011;76:534–9. doi: 10.1212/WNL.0b013e31820b7630. PubMed DOI PMC

Wuerfel J, Sinnecker T, Ringelstein EB, Jarius S, Schwindt W, Niendorf T, et al. Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis. Mult Scler J. 2012;18:1592–9. doi: 10.1177/1352458512441270. PubMed DOI

Mistry N, Dixon J, Tallantyre E, Tench C, Abdel-Fahim R, Jaspan T, et al. Central veins in brain lesions visualized with high-field magnetic resonance imaging: a pathologically specific diagnostic biomarker for inflammatory demyelination in the brain. JAMA Neurol. 2013;70:623–8. doi: 10.1001/jamaneurol.2013.1405. PubMed DOI

Paul F, Wattjes MP. Chronic cerebrospinal venous insufficiency in multiple sclerosis: the final curtain. Lancet. 2014;383:106–8. doi: 10.1016/S0140-6736(13)61912-1. PubMed DOI

Valdueza JM, Doepp F, Schreiber SJ, van Oosten BW, Schmierer K, Paul F, et al. What went wrong? The flawed concept of cerebrospinal venous insufficiency. J Cereb Blood Flow Metab. 2013;33:657–68. doi: 10.1038/jcbfm.2013.31. PubMed DOI PMC

Doepp F, Paul F, Valdueza JM, Schmierer K, Schreiber SJ. No cerebrocervical venous congestion in patients with multiple sclerosis. Ann Neurol. 2010;68:173–83. doi: 10.1002/ana.22182. PubMed DOI

Doepp F, Wuerfel JT, Pfueller CF, Valdueza JM, Petersen D, Paul F, et al. Venous drainage in multiple sclerosis: a combined MRI and ultrasound study. Neurology. 2011;77:1745–51. doi: 10.1212/WNL.0b013e318236f0ea. PubMed DOI

Dawson J. The histology of disseminated sclerosis. Trans Roy Soc Edin. 1916;50:517-740.

Müller K, Kuchling J, Dörr J, Harms L, Ruprecht K, Niendorf T, et al. Detailing intra-lesional venous lumen shrinking in multiple sclerosis investigated by sFLAIR MRI at 7-T. J Neurol. 2014;261:2032–6. doi: 10.1007/s00415-014-7460-2. PubMed DOI

Sinnecker T, Bozin I, Dörr J, Pfueller CF, Harms L, Niendorf T, et al. Periventricular venous density in multiple sclerosis is inversely associated with T2 lesion count: a 7 Tesla MRI study. Mult Scler J. 2013;19:316–25. doi: 10.1177/1352458512451941. PubMed DOI

Gaitán MI, de Alwis MP, Sati P, Nair G, Reich DS. Multiple sclerosis shrinks intralesional, and enlarges extralesional, brain parenchymal veins. Neurology. 2013;80:145–51. doi: 10.1212/WNL.0b013e31827b916f. PubMed DOI PMC

Adams CW, Poston RN, Buk SJ, Sidhu YS, Vipond H. Inflammatory vasculitis in multiple sclerosis. J Neurol Sci. 1985;69:269–83. doi: 10.1016/0022-510X(85)90139-X. PubMed DOI

Sinnecker T, Oberwahrenbrock T, Metz I, Zimmermann H, Pfueller CF, Harms L, et al. Optic radiation damage in multiple sclerosis is associated with visual dysfunction and retinal thinning—an ultrahigh-field MR pilot study. Eur Radiol. 2014;25:122–31. doi: 10.1007/s00330-014-3358-8. PubMed DOI

Marques JP, Kober T, Krueger G, van der Zwaag W, Van de Moortele P-F, Gruetter R. MP2RAGE, a self bias-field corrected sequence for improved segmentation and T1-mapping at high field. NeuroImage. 2010;49:1271–81. doi: 10.1016/j.neuroimage.2009.10.002. PubMed DOI

Fujimoto K, Polimeni JR, van der Kouwe AJW, Reuter M, Kober T, Benner T, et al. Quantitative comparison of cortical surface reconstructions from MP2RAGE and multi-echo MPRAGE data at 3 and 7 T. NeuroImage. 2014;90:60–73. doi: 10.1016/j.neuroimage.2013.12.012. PubMed DOI PMC

Seiger R, Hahn A, Hummer A, Kranz GS, Ganger S, Küblböck M, et al. Voxel-based morphometry at ultra-high fields. A comparison of 7T and 3T MRI data. NeuroImage. 2015;113:207–16. doi: 10.1016/j.neuroimage.2015.03.019. PubMed DOI PMC

O’Brien KR, Kober T, Hagmann P, Maeder P, Marques J, Lazeyras F, et al. Robust T1-weighted structural brain imaging and morphometry at 7T using MP2RAGE. PloS One. 2014;9 doi: 10.1371/journal.pone.0099676. PubMed DOI PMC

Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14. doi: 10.1186/1742-2094-9-14. PubMed DOI PMC

Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176:149–64. doi: 10.1111/cei.12271. PubMed DOI PMC

Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain. 2002;125:1450–61. doi: 10.1093/brain/awf151. PubMed DOI PMC

Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473–7. doi: 10.1084/jem.20050304. PubMed DOI PMC

Jarius S, Franciotta D, Paul F, Bergamaschi R, Rommer PS, Ruprecht K, et al. Testing for antibodies to human aquaporin-4 by ELISA: sensitivity, specificity, and direct comparison with immunohistochemistry. J Neurol Sci. 2012;320:32–7. doi: 10.1016/j.jns.2012.06.002. PubMed DOI

Jarius S, Paul F, Fechner K, Ruprecht K, Kleiter I, Franciotta D, et al. Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. J Neuroinflammation. 2014;11:129. doi: 10.1186/1742-2094-11-129. PubMed DOI PMC

Kister I, Paul F. Pushing the boundaries of neuromyelitis optica: does antibody make the disease? Neurology. 2015 PubMed

Hertwig L, Pache F, Romero-Suarez S, Stürner KH, Borisow N, Behrens J, et al. Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica. Mult Scler J. 2015 PubMed

Jarius S, Paul F, Franciotta D, Waters P, Zipp F, Hohlfeld R, et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol. 2008;4:202–14. PubMed

Paul F, Jarius S, Aktas O, Bluthner M, Bauer O, Appelhans H, et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med. 2007;4:669. doi: 10.1371/journal.pmed.0040133. PubMed DOI PMC

Bennett JL, de Seze J, Lana-Peixoto M, Palace J, Waldman A, Schippling S, et al. Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography. Mult Scler J. 2015;21:678–88. doi: 10.1177/1352458514567216. PubMed DOI PMC

Schneider E, Zimmermann H, Oberwahrenbrock T, Kaufhold F, Kadas EM, Petzold A, et al. Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis. PLoS ONE. 2013;8 doi: 10.1371/journal.pone.0066151. PubMed DOI PMC

Shimizu J, Hatanaka Y, Hasegawa M, Iwata A, Sugimoto I, Date H, et al. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology. 2010;75:1423–7. doi: 10.1212/WNL.0b013e3181f8832e. PubMed DOI

Cree Ba C, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64:1270–2. doi: 10.1212/01.WNL.0000159399.81861.D5. PubMed DOI

Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung H-P, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012;69:239–45. doi: 10.1001/archneurol.2011.216. PubMed DOI

Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS) J Neurol. 2014;261:1–16. doi: 10.1007/s00415-013-7169-7. PubMed DOI PMC

Min J-H, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler J. 2012;18:113–5. doi: 10.1177/1352458511431973. PubMed DOI

Jarernsook B, Siritho S, Prayoonwiwat N. Efficacy and safety of beta-interferon in Thai patients with demyelinating diseases. Mult Scler J. 2012;19:585–92. doi: 10.1177/1352458512459290. PubMed DOI

Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006;63:390–6. doi: 10.1001/archneur.63.3.390. PubMed DOI

Matthews L, Marasco R, Jenkinson M, Küker W, Luppe S, Leite MI, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology. 2013;80:1330–7. doi: 10.1212/WNL.0b013e3182887957. PubMed DOI PMC

Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015;84:1165–73. doi: 10.1212/WNL.0000000000001367. PubMed DOI PMC

Flanagan EP, Weinshenker BG, Krecke KN, Lennon VA, Lucchinetti CF, McKeon A, et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol. 2015;72:81. doi: 10.1001/jamaneurol.2014.2137. PubMed DOI PMC

Susac JO, Hardman JM, Selhorst JB. Microangiopathy of the brain and retina. Neurology. 1979;29:313–316. doi: 10.1212/WNL.29.3.313. PubMed DOI

Susac JO. Susac’s syndrome: the triad of microangiopathy of the brain and retina with hearing loss in young women. Neurology. 1994;44:591–593. doi: 10.1212/WNL.44.4.591. PubMed DOI

Dörr J, Radbruch H, Bock M, Wuerfel J, Brüggemann A, Wandinger KP, et al. Encephalopathy, visual disturbance and hearing loss-recognizing the symptoms of Susac syndrome. Nat Rev Neurol. 2009;5:683–8. doi: 10.1038/nrneurol.2009.176. PubMed DOI

Dörr J, Krautwald S, Wildemann B, Jarius S, Ringelstein M, Duning T, et al. Characteristics of Susac syndrome: a review of all reported cases. Nat Rev Neurol. 2013;9:307–16. doi: 10.1038/nrneurol.2013.82. PubMed DOI

Jarius S, Kleffner I, Dörr JM, Sastre-Garriga J, Illes Z, Eggenberger E, et al. Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. J Neuroinflammation. 2014;11:46. doi: 10.1186/1742-2094-11-46. PubMed DOI PMC

Brandt AU, Zimmermann H, Kaufhold F, Promesberger J, Schippling S, Finis D, et al. Patterns of retinal damage facilitate differential diagnosis between Susac syndrome and MS. PLoS ONE. 2012;7 doi: 10.1371/journal.pone.0038741. PubMed DOI PMC

Ringelstein M, Albrecht P, Kleffner I, Bühn B, Harmel J, Müller A, et al. Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography. Neurology. 2015;85(7):610-8. PubMed

Dörr J, Jarius S, Wildemann B, Ringelstein EB, Schwindt W, Deppe M, et al. Susac syndrome: an interdisciplinary challenge. Nervenarzt. 2011;82:1250–63. doi: 10.1007/s00115-011-3280-0. PubMed DOI

Dörr J, Ringelstein M, Duning T, Kleffner I. Update on Susac syndrome: new insights in brain and retinal imaging and treatment options. J Alzheimers Dis. 2014;42(Suppl 3):S99–108. PubMed

Rennebohm RM, Egan RA, Susac JO. Treatment of Susac’s Syndrome. Curr Treat Options Neurol. 2008;10:67–74. doi: 10.1007/s11940-008-0008-y. PubMed DOI

Saux A, Niango G, Charif M, Morales R, Mura F, Bonafe A, et al. Susac’s syndrome, a rare, potentially severe or lethal neurological disease. J Neurol Sci. 2010;297:71–3. doi: 10.1016/j.jns.2010.07.020. PubMed DOI

Susac JO, Murtagh FR, Egan RA, Berger JR, Bakshi R, Lincoff N, et al. MRI findings in Susac’s syndrome. Neurology. 2003;61:1783–7. doi: 10.1212/01.WNL.0000103880.29693.48. PubMed DOI

Kilsdonk ID, Wattjes MP, Lopez-Soriano A, Kuijer JPA, de Jong MC, de Graaf WL, et al. Improved differentiation between MS and vascular brain lesions using FLAIR* at 7 Tesla. Eur Radiol. 2014;24:841–9. doi: 10.1007/s00330-013-3080-y. PubMed DOI

Sati P, George IC, Shea CD, Gaitán MI, Reich DS. FLAIR*: a combined MR contrast technique for visualizing white matter lesions and parenchymal veins. Radiology. 2012;265:926–32. doi: 10.1148/radiol.12120208. PubMed DOI PMC

Grabner G, Dal-Bianco A, Schernthaner M, Vass K, Lassmann H, Trattnig S. Analysis of multiple sclerosis lesions using a fusion of 3.0 T FLAIR and 7.0 T SWI phase: FLAIR SWI. J Magn Reson Imaging. 2011;33:543–9. doi: 10.1002/jmri.22452. PubMed DOI

Dixon JE, Simpson A, Mistry N, Evangelou N, Morris PG. Optimisation of T2*-weighted MRI for the detection of small veins in multiple sclerosis at 3 T and 7 T. Eur J Radiol. 2013;82:719–27. doi: 10.1016/j.ejrad.2011.09.023. PubMed DOI

Neuromyelitis optica does not impact periventricular venous density versus healthy controls: a 7.0 Tesla MRI clinical study